Stockscreener 앱 받기
243.19
2.91%
-7.30
시장 영업 전:
243.88
0.69
+0.28%
전일 마감가:
$250.49
열려 있는:
$248.18
하루 거래량:
969.80K
Relative Volume:
1.12
시가총액:
$17.52B
수익:
$2.96B
순이익/손실:
$487.70M
주가수익비율:
36.43
EPS:
6.6758
순현금흐름:
$344.00M
1주 성능:
-0.15%
1개월 성능:
-6.39%
6개월 성능:
-1.22%
1년 성능:
+13.25%
1일 변동 폭
$242.32
$251.81
1주일 범위
$227.49
$259.90
52주 변동 폭
$187.43
$322.34
West Pharmaceutical Services Inc Stock (WST) Company Profile
명칭
West Pharmaceutical Services Inc
전화
(610) 594-2900
주소
530 HERMAN O. WEST DRIVE, EXTON, PA
Compare WST vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WST
West Pharmaceutical Services Inc
|
243.19 | 18.05B | 2.96B | 487.70M | 344.00M | 6.6758 |
|
ISRG
Intuitive Surgical Inc
|
493.35 | 172.54B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
177.38 | 50.03B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
80.72 | 38.90B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.16 | 37.07B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.82 | 36.79B | 5.40B | 1.49B | 1.78B | 10.12 |
West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2025-09-15 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-24 | 개시 | Barclays | Equal Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-01-08 | 개시 | Citigroup | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2024-12-12 | 업그레이드 | UBS | Neutral → Buy |
| 2024-02-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-06-16 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-04-11 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-11-30 | 개시 | UBS | Neutral |
| 2022-10-28 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-14 | 개시 | Stephens | Equal-Weight |
| 2020-07-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-04-24 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-12-12 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-07-26 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2019-05-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-04-23 | 개시 | William Blair | Outperform |
| 2018-04-25 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-17 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2017-10-03 | 개시 | Stephens | Equal-Weight |
| 2017-09-15 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-10-28 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-09-21 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2016-03-22 | 개시 | Wells Fargo | Outperform |
| 2010-05-14 | 재확인 | UBS | Neutral |
| 2010-02-23 | 개시 | Jefferies & Co | Buy |
| 2008-12-19 | 개시 | UBS | Neutral |
모두보기
West Pharmaceutical Services Inc 주식(WST)의 최신 뉴스
West Pharmaceutical announces up to $1B share repurchase program - MSN
West Pharmaceutical Services Maintains Quarterly Dividend, Authorizes $1 Billion Share Repurchase - marketscreener.com
West Pharmaceutical Services, Inc. Declares Regular Quarterly Dividend on Common Stock, Payable on May 6, 2026 - marketscreener.com
West Pharmaceutical Declares Quarterly Dividend and Share Repurchase Program - Intellectia AI
West Pharmaceutical clears $1B for stock buybacks and a May dividend - Stock Titan
Why West Pharmaceutical Services (WST) is a Top Growth Stock for the Long-Term - Yahoo Finance
How West Pharmaceutical Services Inc. (WST) Affects Rotational Strategy Timing - Stock Traders Daily
West Pharmaceutical Services launches Synchrony S1 prefillable syringe system - Traders Union
West Pharmaceutical Services (WST) Stock Analysis: A Look At Its 27% Potential Upside - DirectorsTalk Interviews
WST's Q4 earnings & sales beat, SmartDose sale by mid-2026, stock up - MSN
West Pharmaceutical Services, Inc. (NYSE:WST) Sees Significant Increase in Short Interest - MarketBeat
What’s the outlook for West Pharmaceutical Services Inc.’s sectorPrice Action & Technical Confirmation Alerts - mfd.ru
Earnings Release: Here's Why Analysts Cut Their West Pharmaceutical Services, Inc. (NYSE:WST) Price Target To US$319 - 富途牛牛
Cibc World Market Inc. Has $4.88 Million Holdings in West Pharmaceutical Services, Inc. $WST - MarketBeat
Caprock Group LLC Purchases New Shares in West Pharmaceutical Services, Inc. $WST - MarketBeat
How Investors Are Reacting To West Pharmaceutical (WST) GLP-1 Momentum And Upbeat 2026 Sales Guidance - Sahm
How sensitive is West Pharmaceutical Services Inc. to inflationJuly 2025 Catalysts & Consistent Profit Trade Alerts - mfd.ru
West Pharmaceutical Services (WST): Barclays Lowers Price Target - GuruFocus
Stephens Cuts Price Target on West Pharmaceutical Services to $320 From $350, Maintains Overweight Rating - marketscreener.com
West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript - Insider Monkey
West Pharmaceutical Services Q4 Earnings Call Highlights - MarketBeat
West Pharmaceutical Services Signals HVP‑Led Growth Ahead - The Globe and Mail
West Pharmaceutical targets 5%–7% organic revenue growth for 2026 as HVP demand accelerates - MSN
West Pharma forecasts 2026 profit above estimates on strong demand for drug components - 104.1 WIKY
Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations - Investing.com Canada
West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook - Yahoo Finance
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations - Investing.com Nigeria
West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat
West Pharmaceutical Services Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI
West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Finviz
WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up - Finviz
Iron Mountain Projects Double-Digit Growth in 2026 - Investing.com
West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations By Investing.com - Investing.com India
West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance - MarketBeat
West Pharmaceutical Q4 EPS Beats Estimates; Guides 2026 Sales Growth of 5% to 7% - AlphaStreet News
West Pharmaceutical (WST) Exceeds Market Expectations with Stron - GuruFocus
West Pharmaceutical Services, Inc. $WST Shares Sold by ING Groep NV - MarketBeat
West Pharma (WST) Q4 2025 Earnings Call Transcript - The Globe and Mail
West Pharmaceutical Services Posts Solid Q4 and 2025 Results - TipRanks
West Pharmaceutical (WST) Exceeds Revenue Expectations in Q4 - GuruFocus
West Pharmaceutical Services (WST) Projects FY26 Revenue Range - GuruFocus
Q4 Earnings Update: IRM, USFD, and WST Post Solid Q4 Results - Tokenist
Form 8-K WEST PHARMACEUTICAL SERV For: Feb 12 - StreetInsider
West Pharmaceutical Services (WST) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
West Pharmaceutical: Q4 Earnings Snapshot - kare11.com
West Pharmaceutical Servs Q4 Earnings Summary & Key Takeaways - Benzinga
WEST PHARMACEUTICAL SVSC ($WST) Releases Q4 2025 Earnings - Quiver Quantitative
West Pharma shares climb over 5% on strong fourth-quarter results - Investing.com UK
West Pharma shares climb over 5% on strong fourth-quarter results By Investing.com - Investing.com Nigeria
West Pharmaceutical: Q4 Financial Results Overview - Bitget
West Pharmaceutical Services Inc (WST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
1.27%
자본화:
|
볼륨(24시간):